View Financial HealthClaritas Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Claritas Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 05Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and InjuriesClaritas Pharmaceuticals, Inc. outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Phase 1 Study in First Quarter 2022: The first step is completion of their Phase 1 clinical study to demonstrate that R-107 is safe in humans. They expect to complete this study during First Quarter this year. Multiple Phase 2 Studies in 2H 2022: Following completion of the Phase 1 study, they will initiate several Phase 2 clinical studies across multiple clinical indications, as follows: COVID-Related Sepsis: Sepsis is the leading cause of death among COVID-19 patients, and, as they previously announced, a peer-reviewed article was recently published in Scientific Reports disclosing that R-107 effectively preserved multi-organ function in a sheep model of sepsis. These results suggest that R-107 could be a potentially revolutionary new treatment for sepsis. Based on these results, Claritas will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related sepsis and will apply for U.S. governmental grant funding to cover the costs of this study. The costs of the preclinical development of R-107 were covered by approximately USD $20 million of grant funding previously provided through the U.S. Department of Health and Human Services, and Claritas will again seek such funding for the costs of this Phase 2 study as well as the potential follow-on Phase 3 study. The worldwide market for treatment of sepsis was valued at more than USD $600 million in 2020 and is projected to grow to USD $1.6 billion by 2031. COVID-Related ARDS: Acute respiratory distress syndrome ("ARDS") is one of thecommon clinical manifestations of severe COVID-19. As they previously announced, a published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust 2 reported that inhaled nitric oxide significantly improved oxygen levels in patients with severe COVID-related ARDS. They believe that these data validate the potential of R-107 as a therapy for COVID-related ARDS, and, in Q3-Q4 2022, they will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related ARDS. They will apply for U.S. governmental grant funding to cover the costs of this study, as well as the potential follow-on Phase 3 study. According to an analysis by Reports and Data, the global ARDS market was valued at USD 583.8 million in 2018 and is expected to reach USD 934.8 million by the year 2026. PAH: Pulmonary arterial hypertension ("PAH") is a lethal condition, with no cure, resulting from high blood pressure in the lungs. The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 20273. As they previously announced, R-107 is the first and only drug to demonstrate a durable reversal of established disease in a validated animal model of PAH. The data from this study are unprecedented in the scientific literature and suggest that R-107 is a potentially revolutionary new treatment for PAH. Claritas will initiate a Phase 2a clinical study of R-107 in hospitalized patients with PAH by mid-2022, which they expect to complete during Fourth Quarter 2022.공시 • Feb 27Kalytera Therapeutics, Inc. Launches New WebsiteKalytera Therapeutics, Inc. announced the launch of its new website.공시 • Feb 26Kalytera Therapeutics' Listing to Transfer from TSXV Tier 1 to Tier 2The TSX Venture Exchange (TSXV) determined that Kalytera Therapeutics, Inc. has not maintained its Tier 1 Continued Listing Requirements. The Company will therefore be transferred from Tier 1 to Tier 2 in conjunction with its reinstatement to trade.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CLAZ.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CLAZ.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Claritas Pharmaceuticals 배당 수익률 vs 시장CLAZ.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CLAZ.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (CLAZ.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CLAZ.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CLAZ.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CLAZ.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CLAZ.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 06:29종가2026/02/27 00:00수익2021/09/30연간 수익2020/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Claritas Pharmaceuticals, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 05Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and InjuriesClaritas Pharmaceuticals, Inc. outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Phase 1 Study in First Quarter 2022: The first step is completion of their Phase 1 clinical study to demonstrate that R-107 is safe in humans. They expect to complete this study during First Quarter this year. Multiple Phase 2 Studies in 2H 2022: Following completion of the Phase 1 study, they will initiate several Phase 2 clinical studies across multiple clinical indications, as follows: COVID-Related Sepsis: Sepsis is the leading cause of death among COVID-19 patients, and, as they previously announced, a peer-reviewed article was recently published in Scientific Reports disclosing that R-107 effectively preserved multi-organ function in a sheep model of sepsis. These results suggest that R-107 could be a potentially revolutionary new treatment for sepsis. Based on these results, Claritas will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related sepsis and will apply for U.S. governmental grant funding to cover the costs of this study. The costs of the preclinical development of R-107 were covered by approximately USD $20 million of grant funding previously provided through the U.S. Department of Health and Human Services, and Claritas will again seek such funding for the costs of this Phase 2 study as well as the potential follow-on Phase 3 study. The worldwide market for treatment of sepsis was valued at more than USD $600 million in 2020 and is projected to grow to USD $1.6 billion by 2031. COVID-Related ARDS: Acute respiratory distress syndrome ("ARDS") is one of thecommon clinical manifestations of severe COVID-19. As they previously announced, a published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust 2 reported that inhaled nitric oxide significantly improved oxygen levels in patients with severe COVID-related ARDS. They believe that these data validate the potential of R-107 as a therapy for COVID-related ARDS, and, in Q3-Q4 2022, they will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related ARDS. They will apply for U.S. governmental grant funding to cover the costs of this study, as well as the potential follow-on Phase 3 study. According to an analysis by Reports and Data, the global ARDS market was valued at USD 583.8 million in 2018 and is expected to reach USD 934.8 million by the year 2026. PAH: Pulmonary arterial hypertension ("PAH") is a lethal condition, with no cure, resulting from high blood pressure in the lungs. The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 20273. As they previously announced, R-107 is the first and only drug to demonstrate a durable reversal of established disease in a validated animal model of PAH. The data from this study are unprecedented in the scientific literature and suggest that R-107 is a potentially revolutionary new treatment for PAH. Claritas will initiate a Phase 2a clinical study of R-107 in hospitalized patients with PAH by mid-2022, which they expect to complete during Fourth Quarter 2022.
공시 • Feb 27Kalytera Therapeutics, Inc. Launches New WebsiteKalytera Therapeutics, Inc. announced the launch of its new website.
공시 • Feb 26Kalytera Therapeutics' Listing to Transfer from TSXV Tier 1 to Tier 2The TSX Venture Exchange (TSXV) determined that Kalytera Therapeutics, Inc. has not maintained its Tier 1 Continued Listing Requirements. The Company will therefore be transferred from Tier 1 to Tier 2 in conjunction with its reinstatement to trade.